Research Associate I, CFPS Production

Key Responsibilities

• Manufacture and validate CFPS reagents used in BigHat’s high-throughput antibody screening platform including making buffers, media for biomass production and performing QC experiments on reagents.
• Maintain CFPS reagent manufacturing equipment including incubators, centrifuges, and homogenizers.
• Coordinate with lab ops team to request/order supplies for CFPS reagent manufacturing to ensure reliable stock for platform.
• Design and run experiments for development of next generation CFPS extract to optimize yield and purity of next generation antibodies on our platform.
• Keep a detailed record of all experiments using BigHat’s documentation tools, and clearly communicate results and challenges.
• Present experimental plans and results during regular meetings with manager and science teams.

Skills Knowledge and Expertise

• B.S. degree in Biochemistry, Molecular Biology, or related field with 1-2 years of industry experience.
• Experience working with recombinant protein expression from bacterial cultures. Experience with CFPS is highly desired but not required.
• Experience with molecular cloning techniques including primer design, PCR, mutagenesis, Golden Gate Assembly.
• Preferred: Experience and knowledge of protein purification methods including affinity chromatography and SEC.
• Excellent communication skills; organized and works well in small groups.
• Experience with quantitative and/or statistical analysis software is a plus (e.g. Excel, GraphPad Prism, Python, R, etc.)
• Experience with automation and high-throughput tools and robotic instrumentation is a plus.

Total Rewards

• Range of health insurance plan options through Anthem and Kaiser (monthly credit if benefit waived)
• Dental, and vision coverage through Guardian
• Additional well-being benefits through Nayya, OneMedical, Wagmo, Rula, and more
• 401(k) with company match 
• DTO, two weeks of company-wide shutdown, and 12 company holidays
• Paid parental leave

About
BigHat Biosciences designs safer, more effective biologic therapies for patients using machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies. We apply these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.BigHat is a Series B biotech outside San Francisco with a team-oriented, inclusive, and family-friendly culture. Our broad pipeline of wholly-owned and partnered therapeutic programs span many disparate indications with high unmet need, such as cancer, inflammation, and infectious disease. BigHat has raised >$100M from top investors, including Section 32, a16z, and 8VC.